Can someone use a website to learn how to meditate, and then do it well enough to have their MS symptoms improve? Well, maybe. This small study reports that patients who completed an online meditation course reported a significantly higher quality of life, lower depression and anxiety levels and fewer problems sleeping — compared with those in the control group — after eight weeks of the therapy. However, these improvements disappeared six months later.
Online training in meditation based on mindfulness can improve the quality of life for multiple sclerosis (MS) patients while easing depression, anxiety, and sleep problems, a study conducted in Italy reports.
These findings add to the growing body of evidence that interventions able to improve overall well-being can help patients in managing their symptoms. But such benefits are likely not sustained if training is not practiced regularly.
Coordination between patients, doctors, family, and caregivers is something that’s absolutely necessary to top-notch medical care. It happens, but frequently only haphazardly. Now an MS nonprofit, a nonprofit that focuses on bringing patients and doctors together, and a medication company have created a website aimed at that goal. It’s one small step …
MS Path 2 Care, launched in late 2017, brings together the entire MS community — patients, their families, healthcare providers, and national advocacy groups. Its primary aim is shared decision-making between patients, their support partners, and their healthcare team, with the goal of developing enduring bonds between patients and care participants.
1st Patient Enrolls in Phase 3 Trial of ADS-5102 as Way of Improving Walking Ability, Adamas Announces
I used Ampyra (dalfampridine), which claims it can improve walking speed by about 15 percent for a few years. I think it did improve my speed, but it’s an expensive therapy that’s not always affordable, even with payment help from the medication company or a foundation. So, I’m pleased to see that a Phase 3 trial is starting for another walking medicine. Maybe it’ll give Ampyra some competition.
A Phase 3 trial testing an oral once-a-day therapy — ADS-5102 (amantadine) extended-release capsules — in multiple sclerosis patients with walking difficulties has enrolled its first participant, Adamas Pharmaceuticals announced.
The multi-center, double-blind study (NCT03436199) will assess ADS-5102 in about 570 such patients at five sites across the U.S. Eligible patients are being recruited at sites in Colorado, Georgia, New York, North Carolina, and Washington.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?